Skadden-Led SPAC Prices $125M IPO To Fund Biotech Buy
Special purpose acquisition company Panacea Acquisition Corp. debuted in public markets Wednesday after completing a $125 million initial public offering intended to fund a biotechnology acquisition, guided by Skadden Arps Slate...To view the full article, register now.
Already a subscriber? Click here to view full article